Skip to main content
. 2022 Nov 9;12:19055. doi: 10.1038/s41598-022-21448-1

Figure 1.

Figure 1

TP53 mutations are significantly associated with the development of distant metastases after diagnosis in early-stage NSCLC. (A) Overview of study design. (B) Cox regression hazard ratios of each mutation and copy number alteration analyzed, with significant results (α = 0.05) in red. Error bars are Bonferroni-adjusted 95% confidence intervals. (C) Kaplan–Meier curves showing time to first distant metastasis among patients with early-stage disease, stratified by TP53 mutation status in the primary tumor. Error bars are 95% confidence intervals. (D) Cox regression hazard ratios for TP53 mutation for metastasis to individual sites, with significant results (α = 0.05) in red. Error bars are Bonferroni-adjusted 95% confidence intervals. (E) Fraction of patients diagnosed at each stage, stratified by TP53 mutation status. Error bars denote 95% confidence intervals. (F) Kaplan–Meier curves showing overall survival probability stratified by TP53 mutation status, for patients diagnosed with stage I-III disease. Error bars are 95% confidence intervals. Colors for all panels denote primary tumor TP53 mutation status (dark blue: mutant, teal: wild-type). In all Cox regressions, we incorporated age, sex, race, ethnicity, smoking history, stage at diagnosis, and 10 total mutations/copy number alterations as covariates (Methods).